TrialCancer chemotherapy and pharmacology2013

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.

Edward M Wolin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.